Logo image of CME

CME GROUP INC (CME) Stock Fundamental Analysis

USA - NASDAQ:CME - US12572Q1058 - Common Stock

261.96 USD
+0.88 (+0.34%)
Last: 9/23/2025, 8:00:00 PM
261.96 USD
0 (0%)
After Hours: 9/23/2025, 8:00:00 PM
Fundamental Rating

5

CME gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 236 industry peers in the Capital Markets industry. While CME has a great profitability rating, there are some minor concerns on its financial health. CME is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

In the past year CME was profitable.
CME had a positive operating cash flow in the past year.
Each year in the past 5 years CME has been profitable.
CME had a positive operating cash flow in each of the past 5 years.
CME Yearly Net Income VS EBIT VS OCF VS FCFCME Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

1.2 Ratios

The Return On Assets of CME (2.07%) is comparable to the rest of the industry.
The Return On Equity of CME (13.42%) is better than 71.61% of its industry peers.
The Return On Invested Capital of CME (17.96%) is better than 94.07% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for CME is significantly above the industry average of 7.59%.
The 3 year average ROIC (15.81%) for CME is below the current ROIC(17.96%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 2.07%
ROE 13.42%
ROIC 17.96%
ROA(3y)2.17%
ROA(5y)1.91%
ROE(3y)11.65%
ROE(5y)10.5%
ROIC(3y)15.81%
ROIC(5y)11.95%
CME Yearly ROA, ROE, ROICCME Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

CME has a Profit Margin of 34.40%. This is in the better half of the industry: CME outperforms 77.12% of its industry peers.
CME's Profit Margin has declined in the last couple of years.
CME's Operating Margin of 79.34% is amongst the best of the industry. CME outperforms 98.73% of its industry peers.
CME's Operating Margin has improved in the last couple of years.
Industry RankSector Rank
OM 79.34%
PM (TTM) 34.4%
GM N/A
OM growth 3Y9.92%
OM growth 5Y6.02%
PM growth 3Y-13.33%
PM growth 5Y-2.37%
GM growth 3YN/A
GM growth 5YN/A
CME Yearly Profit, Operating, Gross MarginsCME Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80 100

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, CME has about the same amount of shares outstanding.
The number of shares outstanding for CME has been increased compared to 5 years ago.
The debt/assets ratio for CME has been reduced compared to a year ago.
CME Yearly Shares OutstandingCME Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
CME Yearly Total Debt VS Total AssetsCME Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50B 100B 150B

2.2 Solvency

CME has a debt to FCF ratio of 0.83. This is a very positive value and a sign of high solvency as it would only need 0.83 years to pay back of all of its debts.
CME has a better Debt to FCF ratio (0.83) than 91.10% of its industry peers.
CME has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
CME has a better Debt to Equity ratio (0.12) than 79.66% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 0.83
Altman-Z N/A
ROIC/WACCN/A
WACCN/A
CME Yearly LT Debt VS Equity VS FCFCME Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.3 Liquidity

CME has a Current Ratio of 1.02. This is a normal value and indicates that CME is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of CME (1.02) is comparable to the rest of the industry.
CME has a Quick Ratio of 1.02. This is a normal value and indicates that CME is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.02, CME is in line with its industry, outperforming 47.88% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.02
Quick Ratio 1.02
CME Yearly Current Assets VS Current LiabilitesCME Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50B 100B 150B

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 13.22% over the past year.
The Earnings Per Share has been growing by 8.57% on average over the past years. This is quite good.
CME shows a small growth in Revenue. In the last year, the Revenue has grown by 5.41%.
CME shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.14% yearly.
EPS 1Y (TTM)13.22%
EPS 3Y15.32%
EPS 5Y8.57%
EPS Q2Q%15.62%
Revenue 1Y (TTM)5.41%
Revenue growth 3Y26.89%
Revenue growth 5Y13.14%
Sales Q2Q%10.41%

3.2 Future

Based on estimates for the next years, CME will show a small growth in Earnings Per Share. The EPS will grow by 7.38% on average per year.
Based on estimates for the next years, CME will show a small growth in Revenue. The Revenue will grow by 5.14% on average per year.
EPS Next Y9.95%
EPS Next 2Y6.89%
EPS Next 3Y6.76%
EPS Next 5Y7.38%
Revenue Next Year6.51%
Revenue Next 2Y5.4%
Revenue Next 3Y5.34%
Revenue Next 5Y5.14%

3.3 Evolution

The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CME Yearly Revenue VS EstimatesCME Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2B 4B 6B 8B 10B
CME Yearly EPS VS EstimatesCME Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 5 10

2

4. Valuation

4.1 Price/Earnings Ratio

CME is valuated rather expensively with a Price/Earnings ratio of 23.90.
Based on the Price/Earnings ratio, CME is valued a bit more expensive than 60.17% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.41. CME is around the same levels.
With a Price/Forward Earnings ratio of 22.35, CME is valued on the expensive side.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CME indicates a slightly more expensive valuation: CME is more expensive than 61.44% of the companies listed in the same industry.
CME's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.87.
Industry RankSector Rank
PE 23.9
Fwd PE 22.35
CME Price Earnings VS Forward Price EarningsCME Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

87.29% of the companies in the same industry are more expensive than CME, based on the Enterprise Value to EBITDA ratio.
The rest of the industry has a similar Price/Free Cash Flow ratio as CME.
Industry RankSector Rank
P/FCF 22.98
EV/EBITDA 10.69
CME Per share dataCME EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
CME has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.4
PEG (5Y)2.79
EPS Next 2Y6.89%
EPS Next 3Y6.76%

4

5. Dividend

5.1 Amount

CME has a Yearly Dividend Yield of 1.92%. Purely for dividend investing, there may be better candidates out there.
CME's Dividend Yield is slightly below the industry average, which is at 8.21.
CME's Dividend Yield is comparable with the S&P500 average which is at 2.38.
Industry RankSector Rank
Dividend Yield 1.92%

5.2 History

The dividend of CME is nicely growing with an annual growth rate of 16.00%!
CME has paid a dividend for at least 10 years, which is a reliable track record.
CME has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)16%
Div Incr Years11
Div Non Decr Years11
CME Yearly Dividends per shareCME Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2 4 6 8 10

5.3 Sustainability

CME pays out 103.72% of its income as dividend. This is not a sustainable payout ratio.
The dividend of CME is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP103.72%
EPS Next 2Y6.89%
EPS Next 3Y6.76%
CME Yearly Income VS Free CF VS DividendCME Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B
CME Dividend Payout.CME Dividend Payout, showing the Payout Ratio.CME Dividend Payout.PayoutRetained Earnings

CME GROUP INC

NASDAQ:CME (9/23/2025, 8:00:00 PM)

After market: 261.96 0 (0%)

261.96

+0.88 (+0.34%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)07-23 2025-07-23/bmo
Earnings (Next)10-22 2025-10-22/bmo
Inst Owners91.81%
Inst Owner Change-3.5%
Ins Owners0.24%
Ins Owner Change2.06%
Market Cap94.41B
Analysts69.09
Price Target290.5 (10.89%)
Short Float %1.26%
Short Ratio2.23
Dividend
Industry RankSector Rank
Dividend Yield 1.92%
Yearly Dividend9.97
Dividend Growth(5Y)16%
DP103.72%
Div Incr Years11
Div Non Decr Years11
Ex-Date09-09 2025-09-09 (1.25)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.43%
Min EPS beat(2)-1.28%
Max EPS beat(2)0.43%
EPS beat(4)2
Avg EPS beat(4)0.29%
Min EPS beat(4)-1.28%
Max EPS beat(4)2.05%
EPS beat(8)6
Avg EPS beat(8)0.66%
EPS beat(12)10
Avg EPS beat(12)0.99%
EPS beat(16)14
Avg EPS beat(16)1.18%
Revenue beat(2)0
Avg Revenue beat(2)-1.41%
Min Revenue beat(2)-1.72%
Max Revenue beat(2)-1.11%
Revenue beat(4)0
Avg Revenue beat(4)-1.01%
Min Revenue beat(4)-1.72%
Max Revenue beat(4)-0.57%
Revenue beat(8)0
Avg Revenue beat(8)-0.9%
Revenue beat(12)4
Avg Revenue beat(12)11.99%
Revenue beat(16)8
Avg Revenue beat(16)11.42%
PT rev (1m)-0.09%
PT rev (3m)2.67%
EPS NQ rev (1m)-0.13%
EPS NQ rev (3m)-3.05%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.15%
Revenue NQ rev (1m)-0.19%
Revenue NQ rev (3m)-4.2%
Revenue NY rev (1m)-0.09%
Revenue NY rev (3m)-1.63%
Valuation
Industry RankSector Rank
PE 23.9
Fwd PE 22.35
P/S 8.73
P/FCF 22.98
P/OCF 22.5
P/B 3.4
P/tB N/A
EV/EBITDA 10.69
EPS(TTM)10.96
EY4.18%
EPS(NY)11.72
Fwd EY4.47%
FCF(TTM)11.4
FCFY4.35%
OCF(TTM)11.64
OCFY4.44%
SpS30.02
BVpS76.97
TBVpS-7.46
PEG (NY)2.4
PEG (5Y)2.79
Profitability
Industry RankSector Rank
ROA 2.07%
ROE 13.42%
ROCE 23.13%
ROIC 17.96%
ROICexc 19.04%
ROICexgc 145.35%
OM 79.34%
PM (TTM) 34.4%
GM N/A
FCFM 37.97%
ROA(3y)2.17%
ROA(5y)1.91%
ROE(3y)11.65%
ROE(5y)10.5%
ROIC(3y)15.81%
ROIC(5y)11.95%
ROICexc(3y)17.24%
ROICexc(5y)12.98%
ROICexgc(3y)263.94%
ROICexgc(5y)202.43%
ROCE(3y)20.37%
ROCE(5y)15.39%
ROICexcg growth 3Y53.64%
ROICexcg growth 5Y25.03%
ROICexc growth 3Y41.34%
ROICexc growth 5Y22.06%
OM growth 3Y9.92%
OM growth 5Y6.02%
PM growth 3Y-13.33%
PM growth 5Y-2.37%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 0.83
Debt/EBITDA 0.38
Cap/Depr 26.59%
Cap/Sales 0.82%
Interest Coverage 66.07
Cash Conversion 47.06%
Profit Quality 110.37%
Current Ratio 1.02
Quick Ratio 1.02
Altman-Z N/A
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)24.77%
Cap/Depr(5y)29.97%
Cap/Sales(3y)0.96%
Cap/Sales(5y)1.86%
Profit Quality(3y)106.99%
Profit Quality(5y)105.5%
High Growth Momentum
Growth
EPS 1Y (TTM)13.22%
EPS 3Y15.32%
EPS 5Y8.57%
EPS Q2Q%15.62%
EPS Next Y9.95%
EPS Next 2Y6.89%
EPS Next 3Y6.76%
EPS Next 5Y7.38%
Revenue 1Y (TTM)5.41%
Revenue growth 3Y26.89%
Revenue growth 5Y13.14%
Sales Q2Q%10.41%
Revenue Next Year6.51%
Revenue Next 2Y5.4%
Revenue Next 3Y5.34%
Revenue Next 5Y5.14%
EBIT growth 1Y5.85%
EBIT growth 3Y39.48%
EBIT growth 5Y19.95%
EBIT Next Year12.03%
EBIT Next 3Y7.91%
EBIT Next 5Y7.61%
FCF growth 1Y32.16%
FCF growth 3Y16.49%
FCF growth 5Y8.18%
OCF growth 1Y31.45%
OCF growth 3Y15.38%
OCF growth 5Y6.67%